key: cord-0807290-uh1j2rn7
authors: Shakhsi-Niaei, Mostafa; Soureshjani, Ehsan Heidari; Babaheydari, Ali Kazemi
title: In Silico Comparison of Separate or Combinatorial Effects of Potential Inhibitors of the SARS-CoV-2 Binding Site of ACE2
date: 2021-05-03
journal: Iran J Public Health
DOI: 10.18502/ijph.v50i5.6120
sha: 9b953031ab9009a9ade3b1740cc0d833777b1dd7
doc_id: 807290
cord_uid: uh1j2rn7

BACKGROUND: The COVID-19 is a pandemic viral infection with a high morbidity rate, leading to many worldwide deaths since the end of 2019. The RBD (Receptor Binding Domain) of SARS-CoV-2 through its spike utilizes several host molecules to enter host cells. One of the most important ones is the angiotensin-converting enzyme 2 (ACE2), an enzyme normally engaged in renin angiotensin pathway and is responsible for hypertension regulation. As different articles have analyzed separate compounds which can bind ACE2 as the potential virus entry blockers, and each one with a different molecular docking algorithm, in this study we compared all candidate compounds individually as well as their combinations using a unique validated software to introduce most promising ones. METHODS: We collected and prepared a list of all available compounds which potentially can inhibit RBD binding site of the ACE2 from different studies and then reanalyzed and compared them using the Patchdock (ver. 1.3) as a suitable molecular docking algorithm for analysis of separate compounds or their combinations. RESULTS: Saikosaponin A (e.g. in Bupleurum chinense), Baicalin (e.g. in several species in the genus Scutellaria), Glycyrrhizin (Glycyrrhiza glabra), MLN-4760 and Umifenovir better occupied ACE2 to inhibit viral RBD binding and are suggested as the top five inhibitors of the SARS-CoV-2 binding site of ACE2. Their combinatory effects were also inspiring concurrent ACE2 blockade. CONCLUSION: The results propose greatest compounds and their combinatory anti-SARS-CoV-2 effects in order to decrease the time and expenses required for further experimental designs.

The coronavirus (2019-nCoV), the causative organism of novel coronavirus pneumonia, is a positive-sense single-strand RNA virus (1) . In this emergency condition, drug repurposing looks better strategy for virus inhibition or decreasing the signs of the disease (2) . Therefore, according to the pathogenesis of this virus, different drugs could be suggested. The SARS-CoV-2 infection and pathogenesis are consisted of different mechanisms at different levels. The first step is the virus' fusion to the host cells. To develop specific SARS-CoV-2 fusion inhibitors, it is essential to study the fusion capacity of SARS-CoV-2 compared to that of previous severe acute respiratory syndrome coronavirus (SARS-CoV). The SARS-CoV-2 similar to SARS-CoV uses the angiotensin-converting enzyme 2 (ACE2) as the receptor for attaching human cells. In fact, the spike of this virus embarks the first contact and binding to the host cell membrane. The spike (S) protein of SARS-CoVs is made up from S1, S2 and transmembrane subunits. However, S1 located in N-terminal of this protein interacts with the host ACE2 to initialize the fusion step (3) . Despite the high similarities of these two SARS viruses, especially in their S2 subunits of spike protein, their S1 subunits which are responsible for ACE2 interaction, contain more differences. These S1 dissimilarities have led to more than 10fold higher affinity of SARS-CoV-2 to ACE2 in comparison with that of SARS-CoV (4). The same domain of the ACE2 is engaged in S1 binding of these two SARS viruses, repurposing of any available drugs or compounds which can inhibit binding of ACE2 to SARS-CoV would be more promising for SARS-CoV-2, particularly when it has many more affinities to ACE2. So far, the ACE2 receptor has been employed to investigate many compounds for the inhibition of SARS-CoV's entrance, using in silico or experimental strategies. For example, 38 Chinese patent drugs were compared via docking screening for the RBD-binding site masking of ACE2 and more potent ones (hesperidin, saikosaponin A, rutin) introduced as potential viral entrance inhibitors (3). Arbidol, a broad spectrum antiviral drug, has been also reported as an entrance inhibitor via ACE2 blockade (5) . Furthermore, ACE2 binding of some natural compounds were checked and reported Scutellarin as the most potent one (6) . Emodin is a known compound for its anti-SARS activity via anti-ACE2/some-protease activitity (7) (8) (9) (10) . On the other hand, other hypertension modulatorsworking through ACE2 catalytic inhibition, such as N-(2-aminoethyl)-1 aziridine-ethanamine (11) and MLN-4760 (12) has been analyzed for their effects on ACE2 conformational changes and further SARS-S inhibitory effects. Therefore, in this study, we reanalyzed previously evaluated compounds by different molecular docking algorithms or experimental studies (from other related studies) for ACE2 blocking, in order to find the inhibitoriest ones for ACE2 blockade against RBD part of the S1 protein in the SARS-CoV-2.

Considering different studies, the most effective molecules were selected as the ligands for ACE2. In more detail they were chosen from different studies: Hesperidin, saikosaponin A and rutin (3), Umifenovir (Arbidol) (5), scutellarin, glycyrrhizin, baicalin, hesperetin and nicotianamine (6), emodin (7) (8) (9) (10) , N-(2-aminoethyl)-1 aziridine-ethanamine (11) , and MLN-4760 (12) . Therefore, in our study, we analyzed 13 promising compounds by the molecular docking using Patchdock (ver. 1.3) (13). The structures were downloaded from ChemSpider (http://www.chemspider.com) website and optimized with Chimera 1.13.1 software (14) .

The binding structure (S1 protein) of RARS-Cov-2 to ACE2 was modeled according to 6M17 (15) and for SARS-CoV was modeled according to 5WRG (16) obtained from protein data bank (PDB) for further docking analysis. We utilized Patchdock (ver. 1.3) for our molecular docking study (13) . Afterward, the candidate transformations were carried out on complementary patched structures. Then each candidate transformation was compared via the obtained scores by considering the atomic desolvation energy and geometric fit (17) . The PDB coordinate file for each protein and considered ligands made the input parameters for the docking analysis. The clustering RMSD value was set to 4Å. The type of complex was changed to protein-ligand type.

We totally analyzed 13 components by docking to ACE2. According to our docking analysis, top five compounds with higher binding affinities (docking score<about -45 kcal/mol) were identified against ACE2 (by the model of the 6M17) (Table  1) . Interestingly, all of these compounds bind with higher affinity to ACE2 when comparing with SARS-CoV and SARS-CoV-2 viruses. The results of docking analysis of the compounds which may inhibit ACE2 interaction with RBD of SARS-CoV-2 viruses are exposed in Fig. 1 and Table 1 . The characteristics of interacting residues of analyzed compounds with ACE2

The detailed interactions and related residues of ACE2 with 13 investigated compounds are shown in Table 2 . Interacting residues between ACE2

and RBD of SARS-CoV-2 are revealed in Table 3 . Some compounds may occupy the same ACE2 regions by strong hydrogen bonds and therefore, in case of simultaneous application, may interfere each other in ACE2 binding (Table 4 ). *N-Acetyl D-Glucosamine that interacts with mentioned amino acides 

The effect of different binary combination of Top three non-synthetic compounds (Baicalin, Saikosaponin A and Glycyrrhizin) on ACE2 blockade is illustrated in Table 5 . The results uncovered that the first compound may affect the affinity of the second compound in binding to ACE2. 

We analyzed the effects of different ACE2-binding compounds on ACE2:S1 inhibition. Because various studies have suggested different inhibitory compounds based on their applied docking softwares, we were persuaded to analyze the top suggested ACE2-binding compoundsin different articles using a single validated software. Separate softwares have been employed in different studies for these kinds of interaction analysis. For example, the AutoDock Vina can significantly improve the average accuracy of the binding mode predictions when this software is compared with the AutoDock. In fact, the Autodock vina consideres the pockets, cavities, conserved amino acid residues, etc. and then docks them into the predicted binding sites (6) . The SwissDock (http://www.swissdock.ch) server is another suitable tool for blind docking (3). Another employed software widely used in ducking studies is Auto-Dock 4. It consists of autodock and autogrid (3) .

In this research, we used the Patchdock (13) because of its analysis capacity of S1 binding affinity from SARS-CoV-2 with ACE2 in the presence of other compounds. Patchdock algorithm is based on the object recognition and image segmentation techniques used in Computer Vision. This Docking type is comparable with assembling a jigsaw puzzle. The studied compounds are ranked by the binding score. For estimation of this score, Atomic Contact Energy, softened van der Waals interactions, partial electrostatics and additional estimations of the binding free energy are all involved in energy estimation (18) . Therefore, Patchdock results seem to be more comprehensive for ranking different compounds affinity to a molecule. That is why in our study the estimated total energy was greater than its amount in other docking studies benefiting from the Autodock Vina (3, 6) . In our study a selection of top13 ACE2-binding compounds suggested by previous studies were analyzed. The selection consisted of those compounds which can inhibit catalytic domain of the ACE2 for probable conformational changes and decreasing subsequent ACE2:S1 interaction, as well as the ones which could potentially inhibit S1 binding site of the ACE2. According to global energies Baicalin has exhibited anti-oxidative stress, anti-inflammation, and also anti-apoptosis effects. In addition, the antiviral effect of baicalin against SARS-COV has been reported in a primate cell line (6) . Glycyrrhizin is another anti-SARS-CoV promising composition extracted from Chinese Medicine herb Glycyrrhiza radix. It has been previously reported as an effective anti-adsorption and anti-penetration of SARS-CoV in experimental studies. According to abovementioned issues, Baicalin and Glycyrrhizin have been analyzed as the candidates of anti-SARS-CoV-2 investigation besides other compounds, using silico tools (6) . As we checked the combinatorial effect of these medicinal herb metabolites, there is also a good opportunity to benefit from their additive antiviral effects.

MLN-4760 (100 nM) cannot inhibit SARS binding to host cells (12) . However, higher concentration of MLN-4760 is a good candidate for anti-SARS effects (20) . Umifenovir (Arbidol), a recognized antiviral drug by virus-host cell fusion inhibition mechanism, has been entered into a clinical trial for the inhibition of SARS-CoV-2 entrance to the host cells (5) . This drug has a license, for example in Russia, for the antiviral treatment or influenza infection, which can inhibit the replication of human influenza A and influenza B viruses in cell cultures (21) .

Overall, in this study among different suggested medicinal herbs, or synthetic compounds, Saikosaponin A, Baicalin, Glycyrrhizin, MLN-4760 and Umifenovir are suggested as the top five compounds which might inhibit SARS-CoV-2 fusion to host cells via RBD-binding site of the ACE2.

Since the two of above mentioned synthetic drugs do not have any FDA approval or using license, we recommend three remaining suggested medicinal herbs, with a long history of applications, especially for their antiviral effects. Interestingly, there are no obvious antagonistic effects for combinatorial application of these top three medicinal plant compounds. Therefore, we propose separate or combinatorial formulations for achieving the highest SARS-CoV-2 inhibition.

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Discovery of anti-2019-nCoV agents from Chinese patent drugs via docking screening

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases

Potential natural compounds for preventing SARS-CoV-2 (2019-nCoV) infection. Preprints

Silico Identification of Potent

Main Protease Inhibitors from FDA Approved Antiviral Compounds and Active Phytochemicals through Molecular Docking: A Drug Repurposing Approach. Preprints

Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective

Emodin inhibits current through SARS-associated coronavirus 3a protein

Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction

Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2

PatchDock and SymmDock: servers for rigid and symmetric docking

UCSF Chimera-a visualization system for exploratory research and analysis

Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding

Structural basis for the recognition of SARS-CoV-2 by fulllength human ACE2

Understanding Ubl-rpn1 Intermolecular Interaction

Determination of atomic desolvation energies from the structures of crystallized proteins

The role of saikosaponins in therapeutic strategies for age-related diseases

The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients

Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol

The authors would like to express their appreciation to Dr. M. Karbasioun, the professional editor for the great proofreading and improving the quality of the manuscript. The researchers did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The authors declare that there is no conflict of interest.